Background And Methods: The expression of the placental form of glutathione S-transferase (GST-pi) in human squamous cell carcinomas of the pharynx and larynx was investigated immunohistochemically before and after radiation therapy.
Results: Before the treatment, 47 of 71 carcinoma specimens (66.2%) demonstrated positive reactions, GST-pi being diffusely stained throughout the tumor lesions. Positive rates for moderately and well differentiated carcinomas were 69.7% and 88.0%, respectively, with both of these values being significantly higher than that for poorly differentiated carcinomas (15.4%, P < 0.01). Thus, GST-pi expression seems to be related to the degree of differentiation. Although several tumors exhibiting GST-pi staining did not respond to radiation therapy, most cases responded positively and no relation was apparent in the 41 cases of squamous cell carcinoma studied between response to radiation therapy and previous GST-pi staining. After irradiation of 1000 to 7000 cGy, however, most carcinoma specimens exhibited negative GST-pi staining, regardless of response to radiation therapy.
Conclusions: The results suggest that although GST-pi expression is not directly involved in determining sensitivity to radiation, GST-pi expression can be influenced by exogenous agents. The loss or decrease of GST-pi after irradiation is in clear contrast to the enhanced expression observed in many cancer cell lines resistant to chemotherapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/1097-0142(19930715)72:2<569::aid-cncr2820720239>3.0.co;2-7 | DOI Listing |
Perioper Med (Lond)
January 2025
Department of Thoracic Surgery, The Affiliated Huaian No. 1, People's Hospital of Nanjing Medical University, Huaian, 223300, China.
Objective: This retrospective cohort study aims to evaluate and compare different postoperative pain management strategies for esophageal squamous cell carcinoma (ESCC), in order to provide scientific evidence for clinical practice and decision-making.
Methods: A total of 274 ESCC patients who underwent surgery at the Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University were included in the study.
Bull Exp Biol Med
January 2025
Hunan University of Chinese Medicine, Changsha, Hunan, China.
We studied the effect of acteoside on a model of human corneal epithelial cells (HCEC) injury induced by HO. HCEC were divided into 4 groups and cultured for 24 h in normal medium (intact and control groups, respectively), or in a medium containing DMSO or 160 μM acteoside (DMSO and acteoside groups, respectively). Then, HO solution was added to HCEC for 4 h, except for intact cells.
View Article and Find Full Text PDFInflamm Res
January 2025
Department of Emergency Medicine, Institute of Disaster Medicine and Institute of Emergency Medicine, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, 610041, People's Republic of China.
Background: A significant association between immune cells and sepsis has been suggested by observational studies. However, the precise biological mechanisms underlying this association remain unclear. Therefore, we employed a Mendelian randomization (MR) approach to investigate the causal relationship between immune cells and genetic susceptibility to sepsis, and to explore the potential mediating role of blood metabolites.
View Article and Find Full Text PDFNat Cell Biol
January 2025
Department of Genetics, Yale School of Medicine, New Haven, CT, USA.
Skin epithelial stem cells correct aberrancies induced by oncogenic mutations. Oncogenes invoke different strategies of epithelial tolerance; while wild-type cells outcompete β-catenin-gain-of-function (βcatGOF) cells, Hras cells outcompete wild-type cells. Here we ask how metabolic states change as wild-type stem cells interface with mutant cells and drive different cell-competition outcomes.
View Article and Find Full Text PDFNat Rev Clin Oncol
January 2025
Department of Thoracic/Head and Neck Medical Oncology, the University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Immune-checkpoint inhibitors (ICIs) have transformed the treatment paradigm for advanced-stage squamous non-small-cell lung cancer (LUSC), a histological subtype associated with inferior outcomes compared with lung adenocarcinoma. However, only a subset of patients derive durable clinical benefit. In the first-line setting, multiple ICI regimens are available, including anti-PD-(L)1 antibodies as monotherapy, in combination with chemotherapy, or with an anti-CTLA4 antibody with or without chemotherapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!